CGS-21680
CGS-21680
CGS-21680 (pronounced: C-G-S-Two-One-Six-Eight-Zero) is a specific adenosine receptor agonist. It is primarily used in scientific research to understand the function and role of the adenosine A2A receptor.
Etymology
The term CGS-21680 is a systematic name derived from the research code given by the pharmaceutical company Ciba-Geigy (now part of Novartis), which first synthesized the compound. The 'CGS' stands for Ciba-Geigy Substance, and '21680' is a unique identifier.
Usage
CGS-21680 is used in scientific research to study the function and role of the adenosine A2A receptor. It is a selective agonist, meaning it binds to this specific receptor and activates it. This can help researchers understand the effects of the receptor on various biological processes, such as neurotransmission, inflammation, and cardiovascular function.
Related Terms
- Adenosine: A nucleoside and a neurotransmitter in the brain that plays a role in various physiological processes. CGS-21680 is an agonist for one of the receptors of adenosine.
- Agonist: A substance that binds to a specific receptor and triggers a response in the cell.
- Adenosine A2A receptor: A protein that is a member of the adenosine receptor group of G-protein-coupled receptors. CGS-21680 is a selective agonist for this receptor.
- Novartis: A Swiss multinational pharmaceutical company that absorbed Ciba-Geigy, the original synthesizer of CGS-21680.
External links
- Medical encyclopedia article on CGS-21680
- Wikipedia's article - CGS-21680
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski